SR 0379Alternative Names: SR-0379
Latest Information Update: 03 Nov 2015
At a glance
- Originator Osaka University School of Medicine
- Developer Shionogi
- Class Peptide antibiotics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; MTOR protein modulators; Proto oncogene protein c akt modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pressure ulcer